I.A. Bogomolova1,2, D.R. Dolgova1, I.O. Kolodiy1, I.I. Antoneeva1,3
1Ulyanovsk State University, Ulyanovsk
2Federal Scientific and Clinical Center of Medical Radiology and Oncology, Dimitrovgrad
3Regional Clinical Oncological Dispensary, Ulyanovsk
Bogomolova Irina A. ― Assistant of the Department of Physiology and Pathophysiology of the Institute of Medicine, Ecology and Physical Culture of the Ulyanovsk State University, head of the chemotherapeutic department of the Federal Scientific and Clinical Center of Medical Radiology and Oncology
5V Kurchatov Str., Dimitrovgrad, 433507, Russian Federation, e-mail: 73bogomolova@gmail.com, ORCID ID: 0000-0003-3331-8632
Abstract. Chemotherapy (CT) is an important component of the treatment of patients with colorectal cancer (CRC). To date, there are no biomarkers for early prediction of chemoresistance for these patients.
The aim of the study was to assess the prognostic significance of the neutrophil-lymphocyte ratio (NLR) index in the tumor tissue of patients with colorectal cancer.
Material and methods. For a retrospective analysis, the NLR index was assessed in the intraoperatively material of 26 patients with verified colon cancer before special treatment. Groups of platinum-sensitive, platinum-resistant and platinum-refractory patients were distinguished by the time from the end of ACT according to the FOLFOX/XELOX to progression or upon receipt of palliative chemotherapy.
Results. At all stages of CRC, NLR values are significantly higher than those in tissue at the resection line. The NLR index does not significantly differ depending on the patient’s age and tumor differentiation. The risk of recurrence in patients with CRC after adjuvant and palliative chemotherapy according to the FOLFOX/XELOX scheme with NLR more than 1 increases by 2,56 times.
Conclusion. Thus, the determination of the NLR index can be used to assess the prognosis of the sensitivity of patients with colorectal cancer to chemotherapy according to the FOLFOX/XELOX regimen. This indicator can become an additional criterion for stratifying patients according to the risk of progression.
Key words: colorectal cancer, chemoresistance, neutrophil-lymphocyte ratio.